I just got caught up, but I'll take a swing, and others

New Post Public Reply Private Reply Replies (0) Message Board
Buildit hoops #25953
332
I just got caught up, but I'll take a swing, and others feel free to correct me.

1) Joe retired ~3/4 of the NGIO shares. GNBT got 100k shares of preferred shares that appear to be voting only (3000 votes each), as they say they have "no dividend, liquidation or conversion rights and are not subject to redemption".

That means GNBT will always have the 300MM votes for those shares plus how ever many of the ~64MM shares they hold on to after the IPO. So they will have voting control until such time as many more shares have been issued that could wrest that control from them (way, way, way down the road, presumably).

But these shares do not actually have any value or % ownership in NGIO.

2) That means that our ~36MM div shares actually have a huge %ownership in the company (roughly 36%!!! Thanks, Joe!!!).

3) Joe will presumably IPO how ever many shares at ~$5 to raise what he needs to get the parts moving. I would guess he would limit that to as few as possible for now, since he will expect the SP to rise after the IPO. Also, the fewer shares he IPOs, the smaller the float and the more stable the post-IPO price.

So maybe he IPOs 20MM shares, as I believe Bwolfy suggested. That gives him ~$100MM working capital to move forward.

4) Joe could sell further shares on the open market later if he needs to raise further cash. And if there is any vaccine or other partnership success, he will be able to raise more per share. So I wonder if he might IPO a smaller amount initially and wait for that rise.

5) If the deals and their (what I will dub secondary, since they require vaccine approval) "up front" payments come in, that will be substantial for us as shareholders. For example, the China deal is set to pay $50MM upon approval. If that comes thru, that is ~$0.50/sh in cash on the books for NGIO. Pretty substantial.

And just imagine if there is vaccine success leading to purchases at $1.50-$2.50/dose. That adds up quickly. '

6) I wonder what this means for the IPO time frame? The fact that this move was made already makes me think things are in the works. I know Joe said in one of the videos that by Mid-March the IPO would happen. But I really feel that, with this move, it could very well be some time in Feb.


All in all, this seems like a creative piece of Finance work that not only enables the IPO, but also gets cash for Joe to start to develop the businesses... and provides substantial value to shareholders.

This is getting exciting!!! Great job, Joe!!!

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 5

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Recent Trends in Tyler Technologies' Stock

Updated Category News Views 445

A Closer Look at Tyler Technologies' Short Interest Trends Tyler Technologies (NYSE: TYL) has seen a notable shift in its short interest with a recent increase of 3.04%. As per the latest report, the company’s shorted shares currently stand at an impressive 894 thousand, which accounts for about 2.37% of all available shares on the market. This surge in short interest...

Continue Reading
TopBuild's Strategic Acquisition of Seal-Rite Insulation

Updated Category News Views 331

TopBuild's Acquisition Strategy Enhances Growth Potential TopBuild Corp (NYSE: BLD), based in Daytona Beach, is making significant strides in the insulation industry. The company has recently announced its plans to acquire Seal-Rite Insulation, known for its strong foothold in the Omaha and Lincoln markets. This strategic move is poised to strengthen TopBuild's portfolio...

Continue Reading
What Investors Should Know About Stitch Fix Earnings Release

Updated Category News Views 164

Anticipating the Earnings Release for Stitch Fix Stitch Fix, trading under the ticker SFIX, is gearing up to unveil its quarterly earnings. Investors are eagerly awaiting details, particularly given the expectations surrounding the upcoming announcement. Expected Earnings and Market Sentiment Analysts predict that Stitch Fix will report an earnings per share (EPS) of...

Continue Reading
Analyzing Eli Lilly: Resistance Levels and Future Prospects

Updated Category News Views 206

Understanding the Current Trading Conditions for Eli Lilly The trading environment for Eli Lilly and Co (NYSE: LLY) has recently experienced a period of relative calm. Notably, the stock has encountered a resistance level that is affecting its upward mobility. The Dynamics of Market Resistance Resistance levels in the stock market often occur when earlier buyers regret...

Continue Reading
Ray Waddell Named Finalist in Entrepreneur Of The Year Awards

Updated Category News Views 359

Ray Waddell's Nomination for Entrepreneur Of The Year Ernst & Young LLP (EY US) proudly announces Ray Waddell of CEC Facilities Group as a finalist for the Entrepreneur Of The Year 2025 Southwest Award. This award celebrates exceptional entrepreneurs whose innovative ideas and leadership transform industries and drive economic growth. Significance of the Entrepreneur Of...

Continue Reading